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Abstract
ErbB-3 (HER-3) receptor is involved in tumor progression and resistance to therapy. Development of specific inhibitors
impairing the activity of ErbB-3 is an attractive tool for cancer therapeutics. MP-RM-1, a murine monoclonal antibody
targeting human ErbB-3, has shown anticancer activity in preclinical models. With the aim to provide novel candi-
dates for clinical use, we have successfully generated a humanized version of MP-RM-1. The humanized antibody,
named EV20, abrogates both ligand-dependent and ligand-independent receptor signaling of several tumor cell types,
strongly promotes ErbB-3 down-regulation, and efficiently and rapidly internalizes into tumor cells. Furthermore, treat-
ment with EV20 significantly inhibits growth of xenografts originating from prostatic, ovarian, and pancreatic cancers
as well as melanoma in nude mice. In conclusion, we provide a novel candidate for ErbB-3–targeted cancer therapy.
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Introduction
ErbB-3 (HER-3) is one of the four members of the epidermal growth
factor receptor (or ErbB) family. These receptors transduce extracellular
signals into the cell, which strictly regulate key cellular processes such as
proliferation, survival, migration, and invasion. Abnormal ErbB activity
has been reported in several human cancers and is considered a hall-
mark of malignancy [1–5]. As a consequence, ErbB-1 and ErbB-2 re-
ceptors are the most targeted oncoproteins in cancer [6,7].
Although ErbB-3 has significantly reduced kinase activity when
compared to other members of the family [8], its activity has been
documented in several cancers, including breast, lung, prostate, pan-
creas, ovary, and head and neck cancers as well as melanoma [9–15].
ErbB-3 is unique in that it is able to potently activate downstream
phosphatidylinositol-3-kinase (PI3K) through six consensus phospho-
tyrosine sites, not present on ErbB-1 and ErbB-2 [16]. Activated PI3K
results in the recruitment and activation of Akt, a master regulator of
downstream pathways that are implicated in a plethora of processes criti-
cal for tumorigenesis and therapy resistance [17]. Indeed, most tumors
require PI3K/Akt signaling for their survival, which is often achieved
by an abnormally hyperactive upstream receptor ErbB-3 [18].
Therefore, an increasing attention is directed to ErbB-3 as a target
for cancer therapy, documented by the fact that many ErbB-3 in-
hibitors, i.e., monoclonal antibodies (mAbs), are currently under
clinical development [19–21].
We have recently developed a murine mAb, named MP-RM-1, that
specifically recognizes the extracellular domain (ECD) of ErbB-3 [22].
This antibody has been shown to possess strong antitumoral activity
both in vitro and in vivo through the disruption of the ErbB-3/Akt
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signaling pathway, suggesting that MP-RM-1 may represent an excel-
lent candidate for targeted therapy in tumors with activated ErbB-3
[22]. Therefore, in an attempt to develop an agent endowed with a
potential anti-cancer clinical application, we have generated 4 chimeric
and 16 humanized variants of MP-RM-1 and selected the humanized
variant EV20 as the lead compound. Here, we describe the ability of
EV20 to target ErbB-3, downregulate its activity, and internalize it
into tumor cells. Furthermore, we demonstrate that EV20 can inhibit
the growth of several tumor xenografts in nude mice.
Materials and Methods
Antibody Humanization and Chimerization
MP-RM-1 chimeric variants were generated by fusing the variable
domain of the heavy chain and the variable domain of the light chain
of the murine antibody to the corresponding human constant do-
mains. Four variants were generated using IgG1 and IgG3 heavy chain
(HC) subtypes and κ and λ light chain (LC) subtypes. Humanized
MP-RM-1 variants were generated by identifying murine comple-
mentary determinant regions (CDRs) that were grafted onto a human
antibody framework. The IgG1 isotype was used for all humanized
variants. Libraries of human antibodies were screened to identify the op-
timal human framework for the HC and LC. In defining the optimal
framework, long continuous stretches of human sequence in any given
framework region were identified. The HC and LC human frame-
works are based on the accession number sequences CAB37147 and
AAX82494, respectively. Sixteen humanized antibody variants were con-
structed by replacing selected residues in the human framework with
their MP-RM-1 counterparts. Recombinant genes were placed into the
pCDNA3.1 expression vector and transfected into Chinese Hamster
Ovary-S cells. For small/medium-scale production of antibody variants,
transiently transfected Chinese Hamster Ovary-S cells were grown using
a benchtop BioFlo 3000 bioreactor (New Brunswick Scientific, Enfield,
CT); antibody-containing supernatants were purified by ultrafiltration
(VivaFlow-200 membrane; Sartorius Stedim Biotech, Goettingen,
Germany) and immune selection on a Protein-A (Pall Protein A ceramic
HyperD F) affinity matrix. EV20 affinity was determined by surface
plasmon resonance assays as described [23].
Reagents
Antibodies were given as follows: phosphorylated ErbB-3 (Tyr1289),
phosphorylated Akt (Ser473), and Akt from Cell Signaling Technology
(Danvers, MA); C-17 ErbB-3 from Santa Cruz Biotechnology (Santa
Cruz, CA); anti-actin, rhodamine-labeled phalloidin, and protein syn-
thesis inhibitor CHX were purchased from Sigma-Aldrich Corporation
(St Louis, MO). Neuregulin-1β (NRG-1β) and recombinant human
ECD ErbB-3/Fc chimera were purchased from R&D Systems, Inc
(Minneapolis, MN). Recombinant human ECD ErbB-3 was from
ACROBiosystems (Bethesda, MD). F(ab′)2 preparation kit was pur-
chased from Pierce (Thermo Fisher Scientific, Inc, Rockford, IL).
Cell Culture
DU-145 (prostate), Fadu (head and neck), BxPC-3 (pancreas),
MDA-MB-435 (melanoma), Skbr-3, and MDA-MB-361 (breast)
human cancer cells were purchased from American Type Culture Col-
lection (Rockville, MD); OVCAR-8 (ovary) cells were from National
Cancer Institute/National Institutes of Health (NCI/NIH; Frederick,
MD). The human melanoma cell line IR-8 [24] was kindly provided
by Dr Carlo Leonetti (“Regina Elena” NCI, Rome, Italy). The gastric
carcinoma cell line MKN-45 [25] was kindly provided by Dr Sergio
Anastasi (“Regina Elena” NCI). IR-8 4Mut and IR-8 shErbB-3 cells
were generated as described [22,26]. All cell lines were grown in RPMI
1640 or Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad,
CA) supplemented with 10% heat-inactivated FBS (Invitrogen),
L-glutamine, and antibiotics (Sigma-Aldrich Corporation) and incu-
bated in 5% CO2 at 37°C.
Immunoblot Analysis
Lysates from cells in culture were prepared by washing cells twice in
cold phosphate-buffered saline (PBS) followed by lysis with either
HNTG buffer [50 mMHepes (pH 7.5), 150 mMNaCl, 10% glycerol,
1% Triton X-100, and 5 mM EGTA] or RIPA lysis buffer supple-
mented with protease and phosphatase inhibitors (Sigma-Aldrich
Corporation). Immunoblot analysis was performed as described [22].
Western blot (WB) bands were densitometrically quantified using
ImageJ software. To study ErbB-2/ErbB-3 heterodimerization, immuno-
precipitation assays were performed using the anti–ErbB-2 antibody
trastuzumab covalently linked to AminoLink Coupling Resin (Pierce).
Linking of the antibody to the resin was performed overnight at 4°C.
FACS Assays
For ErbB-3 surface expression analysis, cells were incubated on ice
in the presence of 1 μg/ml EV20 for 0.5 hour and then returned to
37°C for 1 hour, harvested, and stained with an Alexa Fluor 488 goat
anti-human antibody (Molecular Probes, Life Technologies, Paisley,
United Kingdom). Alternatively, cells were exposed to increasing doses
of EV20 for 6 hours at 37°C, detached, and incubated with 100 nM of
anti–ErbB-3 (MAB 3481 from R&D Systems, Inc) for 30 minutes at
4°C, followed by Alexa Fluor specific secondary antibodies (Molecular
Probes, Life Technologies). The murine ErbB-3 antibody MAB 3481
does not interfere with EV20 for ErbB-3 binding (data not shown).
After labeling, samples were analyzed by flow cytometry using a FACS
Calibur cytometer (Becton Dickinson, Buccinasco, Italy). Data analysis
to quantify changes in the mean surface receptor fluorescence values
was performed as described [27].
Confocal Microscopy
IR-8 cells grown on coverslips were treated as follows: 1) cells were
incubated with EV20 on ice for 1 hour to induce binding of the anti-
body to the plasma membrane; 2) cells were incubated for different
lengths of time with EV20 together with LysoTracker Red (1 hour)
at 37°C to analyze antibody internalization. Cells were then fixed
in 4% paraformaldehyde for 15 minutes at room temperature, per-
meabilized with 0.25% Triton X-100 for 5 minutes, and blocked with
0.1% BSA for 1 hour at room temperature. Coverslips were then in-
cubated for 2 hours at room temperature with the indicated primary
antibodies, followed by Alexa Fluor specific secondary antibodies
(Molecular Probes, Life Technologies). DRAQ5 (Vinci-Biochem,
Firenze, Italy) was used to visualize nuclei. Images were acquired with
a Zeiss LSM 510 meta-confocal microscope (Zeiss, Oberkochen,
Germany) using 488-, 543-, and 633-nm lasers. Quantification of
co-localization was performed with WCiF ImageJ software, using a
co-localization plug-in.
Soft-Agar Colony Formation Assay
For the anchorage-independent growth assay with IR-8, BxPC-3,
DU-145, and MKN-45 cell lines, 3 × 104 cells were plated per well
in 12-well plates. The assay was then performed as described [22].
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Table 1. Screening of MP-RM-1 Variants.
Antibody Variant Inhibitory Effect (Long-Term) Inhibitory Effect (Short-Term) Down-Regulation K d (nM)
cMP-RM-1 #1 +++ ++++ +++ 1.35
cMP-RM-1 #2 +++ + ++ –
cMP-RM-1 #3 +++ + ++ –
cMP-RM-1 #4 ++++ +/− + –
hMP-RM-1 #5 +++ ++ + –
hMP-RM-1 #6 +++ ++++ +++ 1.74
hMP-RM-1 #7 +++ ++++ ++ –
hMP-RM-1 #8 +++ ++++ ++ –
hMP-RM-1 #9 +++ ++++ ++ –
hMP-RM-1 #10 +++ ++++ +++ 1.16
hMP-RM-1 #11 +++ ++++ ++ –
hMP-RM-1 #12 +++ ++++ ++ –
hMP-RM-1 #13 +++ ++ ++ –
hMP-RM-1 #14 ++++ ++ ++ –
hMP-RM-1 #15 +++ ++ ++ –
hMP-RM-1 #16 +++ + ++ –
hMP-RM-1 #17 ++++ ++ ++ –
hMP-RM-1 #18 +++ ++ + –
hMP-RM-1 #19 +++ ++++ ++ –
hMP-RM-1 #20 ++++ ++++ +++ 1.30
Inhibitory effect (long-term) refers to the inhibition of ErbB-3/Akt phosphorylation in serum-starved (24-hour) IR-8 cells incubated with the antibody variants for 2 hours and then stimulated with
NRG-1β for 5 minutes. Inhibitory effect (short-term) refers to the inhibition of ErbB-3/Akt phosphorylation in serum-starved (24-hour) IR-8 cells co-exposed to antibody variants and NRG-1β for
5 minutes. Down-regulation refers to the ability of the antibody variants to promote ErbB-3 down-regulation in IR-8 cells as evaluated by WB and FACS. K d is determined by surface plasmon resonance.
Antibody isotype is IgG3 for cMP-RM-1 #3 and cMP-RM-1 #4 and IgG1 for all other variants.
Figure 1. EV20 inhibits ErbB-3/Akt activation in both a ligand-dependent and a ligand-independent manner. To study the effect of EV20
on ligand-dependent activation of ErbB-3/Akt, DU-145, IR-8, and OVCAR-8 cells were serum starved for 24 hours and then treated with
increasing doses of EV20 for 2 hours, before stimulation with 10 ng/ml NRG-1β (5 minutes). For ligand-independent assay, the serum-
starved (24-hour) Skbr-3 cells were treated with increasing doses of the antibody for 2 hours and then harvested. Lysates obtained from
cells were immunoblotted as indicated. Immunoreactivity was quantified and plotted after normalization to total Akt. Data are presented
as percentage of inhibition of ErbB-3/Akt phosphorylation in EV20-treated samples over control. The presented data are representative
of two independent experiments.
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Animal Studies
Athymic CD-1 nu/nu mice (5 or 7 weeks old) were purchased from
Charles River Laboratories (Calco, Italy) and maintained under specific
pathogen-free conditions with food and water provided ad libitum. The
animal health status was monitored daily. Procedures involving animals
and their care were conducted according to the institutional guidelines
in compliance with national and international laws and policies. Xeno-
grafts were generated by subcutaneous injection into the right flank of
mice of 5 × 106 (IR-8, BxPC-3, OVCAR-8, and DU-145) or 3 × 106
(MKN-45) cells in 200 μl of PBS. When xenografts became palpable,
animals were divided into two groups (n = 10) in a way to provide a sim-
ilar range of tumor size for each group. In the case of MKN-45 xeno-
graft, six and five mice were used for the control and treated groups,
respectively. The treated group received twice weekly intraperitoneal
injections of 10 mg/kg EV20 in PBS, whereas the control group received
PBS only. Tumor volume was monitored every week by a caliper and
calculated by the following formula: tumor volume (mm3) = (length ×
width2)/2. At the end of the study, mice were anesthetized with iso-
flurane inhalation before cervical dislocation. Tumors were excised and
snap frozen for WB analysis as previously described [26]. For EV20
detection in serum and tumor samples, ELISA was performed as de-
scribed [28], using goat anti-human IgG Fc (Jackson ImmunoResearch,
Newmarket, United Kingdom) as a capture antibody and goat anti-
human HRP (Jackson ImmunoResearch) as the detecting antibody.
Statistics
P values were determined by Student’s t test and considered signifi-
cant for P < .05 (in vivo xenograft experiments, co-localization assays)
or P < .001 (soft agar assay).
Results
Antibody Screening and Lead Selection
Four chimeric and 16 humanized variants of murine MP-RM-1 anti-
body were generated as described in the Materials and Methods sec-
tion. With the aim to identify the antibody variants with the highest
activity, we carried out an initial screening where antibody efficacy
was evaluated as the ability to 1) inhibit ErbB-3/Akt phosphorylation
and 2) promote ErbB-3 down-regulation. Inhibition of ErbB-3/Akt
phosphorylation was assessed both in a long-term assay (cells incubated
with the antibody for 2 hours and then stimulated with NRG-1β for
5 minutes) and a short-term assay (cells co-exposed to antibody and
NRG-1β for 5 minutes).
All the analyzed antibody variants were able to inhibit ErbB-3/Akt
phosphorylation and promote receptor down-regulation. However,
one chimeric (cMP-RM-1 #1) and three humanized (hMP-RM-1
#6, hMP-RM-1 #10, hMP-RM-1 #20) antibodies resulted with the
best score in the screening with no significant differences in affinity
Figure 2. EV20 inhibits ErbB-2/ErbB-3 dimerization without competing with NRG-1β for binding to ErbB-3. (A) MDA-MB-361 cells were
co-exposed to 3 ng/ml NRG-1β and increasing doses of EV20 for 10 minutes. Anti–p-ErbB-3 immunoreactivity was quantified and plotted
after normalization to total ErbB-3. The data are representative of two independent experiments. (B) For FACS, MDA-MB-435 cells were
incubated on ice with increasing concentrations of NRG-1β for 1 hour, then with 0.15 μg/ml EV20 (concentration giving 50% of maximal
binding, as previously determined) for 45 minutes, and finally with the Alexa Fluor 488–conjugated anti-human secondary antibody for
30 minutes. Plotted results are an average ± SD of three independent experiments. (C) For WB, MDA-MB-435 cells were incubated for
1 hour on ice with increasing concentrations of NRG-1β. Cell lysates were probed as indicated. (D) For immunoprecipitation, MDA-MB-361
cells were treated for 30 minutes with 10 μg/ml EV20 and then stimulated for 10 minutes with 10 ng/ml NRG-1β. The lysates were
immunoprecipitated for ErbB-2 and probed as indicated.
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for the receptor (Table 1). Therefore, given the minor immuno-
genicity of humanized compared to chimeric antibodies, hMP-RM-1
#20, hereafter named EV20, was chosen as the lead compound for
further development.
EV20 Inhibits Akt Activation and ErbB-2/ErbB-3
Dimerization without Competing with NRG-1β for
Binding to ErbB-3
To investigate if EV20 is able to interfere with ligand-dependent and
ligand-independent ErbB-3/Akt activation, a panel of cancer cell lines
was treated for 2 hours with increasing doses of EV20. To study NRG-
1β–driven ErbB-3 activation, we used ovarian (OVCAR-8), pros-
tate (DU-145), and melanoma (IR-8) cells. For ligand-independent
ErbB-3 activation, we used the ErbB-2–amplified breast cancer cells,
Skbr-3, that possess constitutive ErbB-3 activity. As shown in Figure 1,
treatment with EV20 dose dependently inhibited ErbB-3/Akt activa-
tion both in the ligand-dependent and ligand-independent models;
moreover, EV20 was able to downregulate receptor levels, although
to variable extents according to the cell line assayed. No effect was ob-
served when cells were exposed to human IgG1 isotype control anti-
body compared to vehicle (PBS), whereas treatment with trastuzumab,
a humanized IgG1 anti–ErbB-2 antibody, produced a strong inhibition
of ErbB-3 and Akt phosphorylation (Figure W1A). Notably, the F(ab′)2
fragment retained the same activity of the full-length (FL) antibody in
terms of inhibition of ErbB-3/Akt phosphorylation (Figure W1B).
We next studied whether EV20 could act as an antagonist for
NRG-1β on ErbB-3 activation. MDA-MB-361 breast cancer cells
co-exposed to 3 ng/mlNRG-1β and increasing doses of EV20 for 10min-
utes showed a dose-dependent inhibition of ErbB-3 phosphorylation,
therefore indicating that the antibody is able to act as a ligand antagonist
Figure 3. EV20 induces ErbB-3 down-regulation. (A) IR-8 cells were maintained for 30 minutes on ice in the presence of 10 μg/ml EV20
and placed back at 37°C for 1 hour. ErbB-3 expression and localization were evaluated by FACS (left) and by confocal microscopy
imaging (right). The histogram represents the percentage of mean fluorescence intensity (MFI) referred to control (cells maintained
on ice). Plotted results are an average ± SD of three independent experiments. For confocal microscopy imaging, EV20 and the early
endosome marker EEA1 were visualized in green and red, respectively. Cell nuclei are shown in blue. (B) IR-8 cells were incubated for
3 hours with 10 μg/ml CHX in the presence or absence of increasing doses of EV20. Lysates were probed with the indicated antibodies.
Anti–ErbB-3 immunoreactivity was quantified and plotted after normalization for actin. (C and D) IR-8 and MKN-45 cells were exposed
to increasing doses of EV20 for 6 hours and then analyzed for surface and total ErbB-3 expression by FACS (C; one representative of
three independent experiments is shown) and WB (D), respectively. Anti–ErbB-3 immunoreactivity was quantified and plotted after
normalization for actin. The data shown in B and D are representative of two independent experiments.
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(Figure 2A). Interestingly, despite these antagonizing properties of the
antibody, FACS analysis demonstrated that EV20 does not compete
with NRG-1β for the ligand binding site of the receptor (Figure 2B).
As a control, phosphorylation of ErbB-3 was assessed by WB in cells
stimulated with NRG-1β, under the same conditions of the FACS assay
(incubation on ice; Figure 2C).
Having demonstrated that EV20 possesses short-term activity, we
investigated whether the antibody is also able to prevent ErbB-2/
ErbB-3 dimerization upon ligand stimulation. We took advantage of
MDA-MB-361 cells, which endogenously express high levels of both
the receptors and in which ErbB-2/ErbB-3 dimerization is inducible
by the ligand. After serum starvation, cells were treated for 30 minutes
with 10 μg/ml EV20, then stimulated for 10 minutes with 10 ng/ml
NRG-1β following which ErbB-2/ErbB-3 dimerization was evaluated
by immunoprecipitation. As illustrated, EV20 completely abolished
NRG-1β–induced ErbB-2/ErbB-3 dimerization (Figure 2D). Taken
together, these data indicate that EV20 exhibits a dual short-term
and long-term activity impairing ErbB-2/ErbB-3 dimerization and
downstream pathway activation.
EV20 Promotes ErbB-3 Down-Regulation
To further investigate ErbB-3 down-regulation induced by EV20,
IR-8 cells were exposed to the antibody on ice for 0.5 hour, then to
37°C for 1 hour, after which ErbB-3 surface expression was analyzed
by FACS. As illustrated in Figure 3A, surface expression of the
receptor was reduced by approximately 60% in cells incubated at
37°C compared to the control group that remained on ice, suggesting
receptor/antibody internalization. This was confirmed by confocal
microscopy (Figure 3A, right).
Moreover, cells treated with the protein synthesis inhibitor CHX in
the presence of the antibody displayed a remarkable, dose-dependent
reduction of ErbB-3 expression compared to those exposed to vehicle
(PBS), indicating the ability of EV20 to accelerate receptor degrada-
tion (Figure 3B). The same results were obtained when using the
F(ab′)2 fragment instead of the FL antibody (Figure W1C). To esti-
mate the “net” effect of the antibody on ErbB-3 levels, we used IR-8
and MKN-45 cells (as ligand-dependent and ligand-independent mod-
els, respectively) for a long-term (6-hour) treatment with increasing
concentrations of EV20 in the presence of serum and in the absence
of NRG-1β and CHX. As depicted, in both cell lines, the anti-
body dose-dependently reduced both the surface and total ErbB-3
expression (Figure 3, C and D, respectively). Constitutive activity of
ErbB-3 in MKN-45 cells was significantly abrogated by treatment with
the antibody (Figure 3D). The ability of EV20 to reduce ErbB-3
expression on the cell surface was confirmed in a panel of cancer cells,
although with variable efficiency depending on the cell line used
(Figure W1D).
Figure 4. EV20 internalizes into IR-8 cells. IR-8 cells were maintained on ice for 1 hour or placed at 37°C for the indicated times in the
presence of 10 μg/ml EV20. EV20 is visualized in green and cadherin (A) and LysoTracker Red (B) in red. Cell nuclei are shown in blue.
Co-localization index values of EV20/cadherin (A) and EV20/LysoTracker Red (B) were obtained by analyzing five different fields for each
point in two independent experiments and reported as means ± SD in the histograms. *P < .05, **P < .01. Bar, 10 μm.
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EV20 Efficiently Internalizes into Tumor Cells
To further analyze EV20 internalization, IR-8 cells were incu-
bated with the antibody (10 μg/ml) on ice for 1 hour or at 37°C for dif-
ferent times. Quantitative immunofluorescence analysis showed that
cells on ice displayed a complete co-localization of signals from EV20
and cadherin at the plasma membrane, whereas, on incubation at
37°C, co-localization was reduced in a time-dependent manner, reach-
ing a nadir after 60 minutes. In a reverse approach, cells were incubated
with EV20 in the presence of LysoTracker Red to identify the lysosomal
compartment. Under these conditions, a time-dependent increase in
co-localization of EV20/LysoTracker Red was observed (Figure 4).
Moreover, tracking the receptor using an anti–ErbB-3 antibody that
recognizes the C-terminal residue (C-17), thus not competing with
EV20, resulted in the co-localization of the two antibodies, indicating
that internalized EV20 was still bound to the receptor (Figure W1E).
The internalization is dependent on ErbB-3 expression, as neither
EV20 binding to cell membrane nor intracellular localization of the
antibody was seen in ErbB-3 silenced cells (Figure W2A), which
displayed an about 80% reduction in the level of the receptor and an
almost complete abrogation of ErbB-3/Akt activation (Figure W2,
B and C).
EV20 Exerts Antitumor Activity In Vitro and In Vivo
Finally, we studied the in vitro and in vivo antitumor efficacies of
EV20 by performing colony formation assays and xenograft experi-
ments, respectively. To this end, we used a panel of cancer cell lines
Figure 5. EV20 exerts antitumor activity in vitro and in vivo. (A) The effect of EV20 on anchorage-independent cell growth of IR-8, BxPC-3,
DU-145, and MKN-45 cells was evaluated by determining the number of colonies formed in soft agar. Data are an average ± SD of three
experimental replicates. *P< .001. (B and C) DU-145, IR-8, OVCAR-8, BxPC-3, and MKN-45 cells were injected into recipient mice. Animals
were treated twice a week with 10 mg/kg EV20 or with vehicle alone (PBS). Tumor growth was assessed as described in the Materials and
Methods section. *P< .05. (D) WB analysis of tumor lysates of OVCAR-8 xenografts excised after 6 hours of treatment with 10mg/kg EV20
or PBS. Anti–ErbB-3 immunoreactivity was quantified and plotted after normalization to actin. *P < .01.
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originating from different solid tumors, including gastric (MKN-45),
pancreatic (BxPC-3), prostatic (DU-145), and ovarian (OVCAR-8)
carcinomas and melanoma (IR-8). As shown in Figure 5A, EV20
dose-dependently reduced colony formation in all cell lines.
For the in vivo study, EV20 was administered twice a week as a
single agent at the dose of 10 mg/kg. This treatment resulted in a
significant reduction in tumor volume in all models studied com-
pared to their control groups, respectively. The volume was reduced
by more than 50% in DU-145 and IR-8 xenografts and by about
70% in OVCAR-8 and BxPC-3 xenografts, respectively (P < .05;
Figure 5B). A similar trend, although not significant, was observed
in the MKN-45 xenograft group (Figure 5C ).
Immunoblot analysis of ErbB-3 in tumor xenografts taken from
mice 6 hours after a single dose injection of 10 mg/kg EV20 revealed
a marked reduction of receptor expression, indicating that EV20 is
able to mediate ErbB-3 down-regulation in vivo (Figure 5D). Finally,
concentrations of EV20 in tumor tissue and serum of mice taken
24 hours after the last antibody injection ranged between 110 and
130 ng/mg tissue and 540 and 740 ng/ml, respectively (Figure W2D).
Discussion
ErbB-3 plays a relevant role in the progression of several malignancies
[3,11], and its expression is associated with a reduction in survival
rates in patients affected by several different types of solid tumors
[9]. Recent data have documented for the first time ErbB-3 onco-
genic mutations in many cancer types but most prevalent in patients
with gastric and colon cancers [29]. Additionally, ErbB-3 is involved
in drug resistance in several cancer models. For example, ErbB-3 is
activated by c-MET in lung cancer cells resistant to the ErbB-1 inhibi-
tor gefitinib [30], and its overexpression has been found to be associ-
ated with resistance to ErbB-2 inhibitors in ErbB-2–amplified breast
cancer and to the anti–ErbB-2 antibody pertuzumab in ovarian cancer
[31]. Recently, feedback up-regulation of ErbB-3 has been described
in breast cancer cells treated with PI3K inhibitors or the dual ErbB-2/
ErbB-1 inhibitor lapatinib [32,33] and in melanoma cells treated with
RAF/mitogen-activated protein kinase kinase (MEK) inhibitors [34].
These data indicate that ErbB-3 may represent an important
therapeutic target, and as such, focus has been directed toward the
development of ErbB-3 inhibitors to be used as anticancer agents in
the clinical setting [19–21].
Recently, we have generated a murine mAb targeting ErbB-3,
which possessed anticancer activity in vitro and in vivo [22]. How-
ever, the use of murine antibodies in humans is severely limited by the
development of a human anti-murine antibody response occurring in
up to 50% of patients, which compromises the safety, efficacy, and
biologic half-life of these reagents [35].
Recombinant DNA technology has allowed to largely overcome
human anti-murine antibody response through the chimerization
or humanization of murine mAbs [36]. In this work, 4 chimeric and
16 humanized variants of the murine MP-RM-1 antibody were gen-
erated by the fusion of the MP-RM-1 variable domain of the heavy
chain and variable domain of the light chain portions to the corre-
sponding human constant domains and by grafting the CDRs LC
andHC into a human framework, respectively. All variants were shown
to possess antigen binding capabilities comparable to that of the parent
antibody, as measured by FACS or ELISA (data not shown). These
results are consistent with the fact that all the antibody variants share
the same parental CDRs, only differing for selected amino acids in the
framework region. Moreover, all the antibodies were able to interfere
with ErbB-3/Akt activation and reduce receptor activity, although with
differing efficacies. The humanized variant EV20 was selected as the
lead compound.
EV20 possessed a dissociation constant (K d) of 1.3 nM, as deter-
mined by surface plasmon resonance. Cell binding experiments, per-
formed by FACS assay and ELISA using the ECD of human ErbB-3,
confirmed that the affinity of EV20 for the receptor is in the nano-
molar range (data not shown). We observed no significant variation in
K d values between the parental and humanized antibodies (0.4 and
1.3 nM, respectively), indicating that the humanization process has
not significantly affected its affinity, although it should be noted that
these values are substantially higher than that previously reported for
the murine antibody (K d = 32 nM) [22]. This difference is likely de-
pendent on the type of antigen used. Indeed, in our previous analysis,
ErbB-3 ECD was in a dimeric state because of a fused Fc tail, whereas,
in the present analysis, ErbB-3 ECD was monomeric.
EV20 demonstrated the capacity to impair ligand-dependent and
ligand-independent ErbB-3/Akt activation. Moreover, we show that
this antibody is able to antagonize the NRG-1β–induced ErbB-2/
ErbB-3 dimerization without competing with the ligand for bind-
ing to the receptor. Therefore, it is reasonable to speculate that
EV20, once bound to ErbB-3, induces a conformational change in
the receptor that, despite allowing NRG-1β binding, impairs ErbB-3
heterodimerization and phosphorylation. Identification of the epitope
and critical residues for EV20 binding to ErbB-3 ECD is currently
under investigation.
In addition to the short-term activity, EV20 was able to dramati-
cally reduce ErbB-3 activity in a long-term treatment. Indeed, we
were able to demonstrate that a 2- to 6-hour treatment with EV20 1)
reduces ErbB-3 at the cell surface, 2) accelerates ErbB-3 degradation,
and 3) reduces total ErbB-3 expression.
Another important feature of EV20 is its ability to efficiently inter-
nalize into tumor cells. Using quantitative immunofluorescence analy-
sis, we found that more than 50% of the antibody internalized after
30 minutes and this internalization was strictly dependent on ErbB-3
expression level, as it was not evidenced in cells silenced for ErbB-3.
In vivo antitumor activity of EV20 was also assessed in this study.
The antibody treatment proved to be effective in inhibiting growth
of prostatic, ovarian, pancreatic tumor, and melanoma xenografts.
Although not significant, possibly because of the very aggressive be-
havior of cells in vivo and of the small sample size in the experiment,
similar trends were obtained with tumor xenografts from the c-MET–
addicted MKN-45 gastric cancer cells. We have previously demon-
strated that tumors from animals treated with the murine MP-RM-1
antibody display a significant lower cell proliferation activity in vivo, as
measured by Ki-67 staining and cell mitotic index [22]. In this work,
we confirmed that treatment with EV20 was able to strongly promote
receptor down-regulation in vivo.
The ability of EV20 to promote receptor down-regulation makes
this new antibody an attractive candidate for ErbB-3–targeted cancer
therapy. In fact, recent findings underscore the notion that ErbB-3
up-regulation mediated by forkhead box transcription factors may be
a general mechanism by which the cancer cells treated with targeted
drugs adopt to bypass the block of signaling pathways [32–34].
While the use of naked antibodies is an interesting approach to treat
patients with ErbB-3–positive cancer, the generation of an ErbB-3–
based antibody–drug conjugate could also represent a substantial
improvement over this immunotherapeutic approach [37]. As such,
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the ability of EV20 to efficiently and rapidly internalize into ErbB-3–
expressing tumor cells makes this antibody an ideal candidate for the
generation of an antibody–drug conjugate with the potential of block-
ing tumor growth by a dual mechanism, i.e., by directly interfering
with ErbB-3 signaling and by delivering drug/payload into ErbB-3–
expressing tumor cells.
In conclusion, our findings demonstrate that EV20 antibody has
the therapeutic potential to target and inhibit ErbB-3–dependent can-
cer growth in a clinical setting and therefore warrants further research
and development.
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Figure W1. (A) After 24 hours of serum deprivation, OVCAR-8 cells were treated for 2 hours as indicated before ligand stimulation
(5 minutes). hIgGs and trastuzumab were used as negative and positive control antibodies, respectively. (B) Serum-starved (24-hour)
IR-8 cells were incubated with the FL EV20 or F(ab′)2 truncated form for 2 hours before NRG-1β stimulation. Cell lysates were immuno-
blotted as indicated. (C) IR-8 cells were incubated for 3 hours with CHX in the presence or absence of FL EV20 or F(ab′)2 truncated form.
Cell lysates were immunoblotted as indicated. (D) Cells were exposed to increasing doses of EV20 for 6 hours and then analyzed for
surface ErbB-3 expression by FACS. Plotted results are an average ± SD of three independent experiments. (E) IR-8 cells were treated
with 10 μg/ml EV20, kept on ice for 30minutes, and then returned at 37°C for 180minutes. After harvesting, cells were fixed, permeabilized,
and then incubated with the rabbit antibody C-17 recognizing the C-terminal residue of ErbB-3. Secondary goat anti-human and anti-rabbit
antibodies were used to visualize EV20 (green) and ErbB-3 (red). Cell nuclei are shown in blue. Bar, 10 μm.
Figure W2. (A) Control 4Mut and shErbB-3 IR-8 cells were maintained on ice for 30 minutes in the presence of 10 μg/ml EV20 and
returned at 37°C for 60 minutes. EV20 and ErbB-3 receptor were visualized in green and red, respectively. Cell nuclei are shown in blue.
Bar, 10 μm. (B) Control and shErbB-3 IR-8 cells were analyzed by FACS for ErbB-3 expression. Plotted results are an average ± SD of
three independent experiments. (C) Control and shErbB-3 IR-8 cells were serum starved for 24 hours and then stimulated with 10 ng/ml
NRG-1β for 5 minutes. Cell lysates where then probed with the indicated antibodies. (D) ELISA for determination of EV20 concentration
in serum (left) and tumor tissue (right) of mice 24 hours after antibody injection.
